For the year ending 2025-12-31, RXST had $3,243K increase in cash & cash equivalents over the period. -$19,341K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -38,944 |
| Depreciation and amortization | 3,266 |
| Provision for bad debts | 32 |
| Amortization of debt issuance costs and premium | 0 |
| Loss on extinguishment of debt | 0 |
| Amortization of discount on short-term investments | 8,517 |
| Stock-based compensation | 31,612 |
| Provision for excess and obsolete inventory | 1,932 |
| Accounts receivable | -6,655 |
| Inventories | 11,482 |
| Prepaid and other assets | -1,183 |
| Accounts payable | 627 |
| Accrued expenses and other liabilities | -1,875 |
| Net cash used in operating activities | -15,511 |
| Purchases of property and equipment | 3,830 |
| Maturity of short-term investments | 260,000 |
| Purchase of short-term investments | 239,281 |
| Net cash (used in) provided by investing activities | 16,889 |
| Proceeds from term loan | 0 |
| Repayment of term loan | 0 |
| Proceeds from issuance of common stock from public offering | 0 |
| Proceeds from issuance of common stock | 3,951 |
| Payments for employee taxes related to stock compensation | -2,062 |
| Principal payments on finance lease liabilities | 26 |
| Payments of deferred offering costs | 0 |
| Payments of debt issuance costs | 0 |
| Net cash provided by financing activities | 1,863 |
| Effect of foreign exchange rate on cash, cash equivalents and restricted cash | 3 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 3,243 |
| Cash, cash equivalents and restricted cash - beginning of period | 17,456 |
| Cash, cash equivalents and restricted cash - end of period | 20,699 |
RxSight, Inc. (RXST)
RxSight, Inc. (RXST)